Objective. To perform external validation of a provisional definition of disease flare in patients with gout.
validated gout flare definition will improve the ascertainment of an important clinical outcome in studies of gout.
Disease flares (also known as attacks) are a defining characteristic of gout (1) . Despite the recognized importance of disease flares as an outcome measure (2), a validated method to define gout flares in research is lacking. Definitions used or evaluated in previous studies include the mention of flares in medical records (3) , billing claims data using diagnostic codes for gout (4, 5) , patient self-report (6) , use of drugs commonly prescribed to treat gout flares (nonsteroidal antiinflammatory agents, colchicine, steroids) (7), and empirical definitions based on the most commonly recognized gout flare characteristics (e.g., joint pain, joint swelling, time to peak symptoms) (8) .
In an effort to develop a gout response criterion (2,9), we previously presented 2 definitions for gout flares based entirely on patient-reported criteria, which were strongly associated with a diagnostic standard (gout flare defined by an independent expert rheumatologist evaluating the patient). The definitions were based on the "number of criteria" approach, with peak diagnostic accuracy when at least 3 of the 4 criteria (patient-defined gout flare, pain at rest score >3 on a 0-10-point numerical rating scale [NRS] , presence of at least 1 swollen joint, and presence of at least 1 warm joint) were present, and on a classification and regression tree (CART) algorithm that used only the pain score on an NRS and self-reported flare criteria. These 2 definitions were considered to be provisional, because the small sample size used to derive the definitions did not allow for a validation process, which is necessary when developing clinical criteria or definitions (10) .
The objective of the current study was to validate the previously published provisional definitions of gout flare by determining their accuracy and diagnostic properties in a diverse and larger independent international patient sample.
PATIENTS AND METHODS
Study participants. Patients with established gout were enrolled during a routine or urgent care visit at 17 international rheumatology clinics between October 2015 and September 2016. The only inclusion criteria were fulfillment of the American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2015 classification criteria for gout (11) , age 18 years or older at the time of enrollment, and provision of written informed consent. The study was approved by the coordinating center (University of Alabama at Birmingham) and local institutional review boards at all study sites. A gout patient partner (Rob Hughes, Christchurch, New Zealand) was involved in the manuscript preparation phase and review of the manuscript.
Clinical evaluation. Study sites had either 2 investigators (one of whom was a diagnostic standard investigator) or a research associate and a diagnostic standard investigator. Rheumatologists with considerable experience in the diagnosis and management of gout were considered to be the diagnostic standard ("investigator-defined flare"); no further cross-site training was offered. Training of the study site investigators in the protocol procedures was performed during a face-to-face meeting in San Francisco in November 2015 and through dissemination of instructive slides and follow-up electronic conversations to answer specific queries. Patient data collected by the research associate or investigator during clinical evaluations included age, sex, race/ethnicity, and year of disease onset.
Criteria from the 2012 provisional gout flare definition (10) were evaluated as follows: patient self-reported flare was assessed with the question, "Are you having a gout attack (flare) today?" The swollen joint criterion was assessed with the question, "Are any of your joints swollen?" and the warm joint criteria with the question, "Are any of your joints warm to touch?" These 3 questions had a yes/no answer option. The pain criterion was assessed with the sentence: "Considering pain from your gout over the last 1 week when you are resting (for example in bed or sitting quietly) please circle the number indicating the level of pain when it was at its worst" (determined using a 0-10-point NRS). It was left to the discretion of the study site investigators whether to let the patients complete the questionnaires, to have an investigator or research assistant query or actively assist the patient with the questionnaire, or to use a combination of these methods. Diagnostic standard investigators were asked the question, "Do you believe the patient is having a gout attack (flare) today?" As mentioned above, the diagnostic standard investigators responded to this question without knowing the answers provided by the patient to the other site investigator or research associate.
In addition, a gout patient's global assessment score (on a 0-10-point NRS), the anatomic location of swollen and warm joints, the duration of the gout flare (if present), gout medications used, and information confirming that the patient fulfilled the ACR/EULAR classification criteria for gout were collected. All questionnaires were available in English, and when appropriate, were translated by the site investigator or a professional medical translator to the language spoken at the local study sites.
Power and sample size. We sought to replicate the sensitivity and specificity of the 2012 provisional definitions (for the number of criteria approach, sensitivity of 91% and specificity of 82%) (10) . Using the investigator defined-flare as a diagnostic standard and a margin of error no greater than 5%, the sample size required to replicate a sensitivity of 90% required enrolling 139 patients experiencing flare. To replicate a specificity of 80%, we needed to enroll 246 patients who were not experiencing a flare.
Statistical analysis. Univariate descriptive statistics were used to examine the association of all variables with investigatordefined flare status by comparing means and SDs (continuous data) or frequencies (categorical data). We determined the diagnostic performance of the previously published 2012 provisional definitions for sensitivity, specificity, positive predictive value, and negative predictive value compared with that of the diagnostic standard provided by the expert rheumatologist. The Clopper-Pearson method was used to assess 95% confidence intervals for sensitivity and specificity (12) , and the standard logit-transformed confidence intervals were used to assess predictive values (13) . We tested the number of criteria approach at each level (no criteria met, ≥1 criteria met, ≥2 criteria met, ≥3 criteria met, and all 4 criteria met). We generated a receiver operating characteristic (ROC) curve based on a logistic regression equation to confirm the validity of the rule. The Youden index (sensitivity -[1-specificity]) was used to evaluate the different cut points for the number of criteria approach in the ROC. The CART algorithm published in 2012 (10) was defined for this analysis as a combination of patient-defined gout flare and a pain at rest score of >3 and also tested for its diagnostic performance against the diagnostic standard of investigatordefined gout flare. All descriptive and regression analyses were conducted using SAS Enterprise Guide software, version 4.3 for SAS/STAT 9.4.
RESULTS
Patient characteristics. We enrolled 512 patients from 17 international sites. In 3 patients, gout flare status was not adjudicated, leaving a total of 509 patients who were eligible for analysis (157 with a flare and 352 without a flare according to the diagnostic standard investigator). The characteristics of the patients are shown in Table 1 . The mean AE SD age of the patients was 57.5 AE 13.9 years, and 89% were men. The mean AE SD disease duration was 12.3 AE 10.3 years, 36% of the patients had tophi, and 75% of the patients were currently receiving urate-lowering therapies. Patients experiencing flares according to the diagnostic standard investigator had higher pain scores on an NRS, were less likely to receive urate-lowering therapies, and were more likely to have tophi compared with patients without gout flares. Thirty-one percent of patients reported a self-defined gout flare at the time of evaluation. Among the whole study population, 43% of patients reported having at least 1 swollen joint, 31% reported having at least 1 warm joint, and 38% reported having a pain at rest score of >3 of 10 on the NRS. There was high concordance between patients and diagnostic standard investigators about the presence of a gout flare. Of 159 patientdefined gout flares, 138 (88%) were in agreement with the opinion of the diagnostic standard investigator. Of 157 flares reported by the investigator, 138 (88%) were in agreement with the opinion of the study patients.
Validation of gout flare definitions. Table 2 shows the performance of the number of criteria and the CART provisional definitions against the diagnostic standard provided by the current study data. We observed that the number of criteria definition requiring fulfillment of at least 3 of 4 criteria was 85% sensitive and 95% specific for confirming the presence of a flare in patients with gout. The diagnostic accuracy (true positives + true negatives/total number of patients) for fulfillment of at least 3 of 4 criteria was the highest (92%) for all of the cut points in the number of criteria definition. The ROC curve for the number of criteria definition had an area under the curve value of 0.969 with a high Youden index (sensitivity -[1 -specificity]) value for the presence of at least 3 of 4 criteria (Figure 1 ). The previously published definition based on a CART algorithm (entry point pain at rest score of >3 followed by patientdefined flare "yes") (10) was 73% sensitive and 96% specific ( Table 2) .
DISCUSSION
Gout flares are responsible for a significant proportion of the disease burden in patients and are highly correlated with worsening functional status and disability over time (14) . Herein, we report validation of our previously published definitions for flares in patients with gout, using a large international sample. We confirmed that the number of criteria definition is sensitive, specific, and accurate in identifying such characteristic painful episodes. This definition is, at the moment, intended only for classification of gout flares in the context of clinical research in patients known to have gout, because it has not been validated for use in clinical practice. More investigation is necessary to determine whether this, or a similar gout flare definition, can be applied in clinical practice. * The number of criteria definition included patient-defined gout flare, pain at rest score >3 on a 0-10 numerical rating scale, presence of at least 1 swollen joint, and presence of at least 1 warm joint. The classification and regression tree (CART) definition included only pain at rest score >3 and patient-reported flare. 95% CI = 95% confidence interval; PPV = positive predictive value; NPV = negative predictive value. 
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The definition using number of criteria with a cut point of at least 3 of 4 has higher diagnostic accuracy (92% versus 84%) compared with its initial performance in the smaller cohort previously described in 2012 (10) . The definition based on a CART algorithm (10) did not have acceptable sensitivity (only 73%) in this validation study. We support use of the number of criteria approach rather than the CART algorithm, based on current study data showing that the cut point of 3 of 4 criteria had higher accuracy relative to the CART algorithm-based approach (92% versus 89%), as well as much better sensitivity (85% versus 73%). In the current validation study, the ROC Youden index (sensitivity -[1 -specificity]) was marginally superior for the number of criteria cut point of 2 or more compared with 3 or more (Figure 1) , with both exhibiting almost identical diagnostic accuracy (Table 2 ). However, in the original report of provisional definitions, the cut point of 2 or more criteria was decidedly inferior compared with the cut point of 3 or more criteria (10) . In view of the excellent performance and acceptable face validity of the provisional definitions, in the current study we decided to concentrate our efforts on validation of those definitions of gout flare instead of generating new ones.
The strengths of our analysis include the use of a large, diverse, and routine practice-based sample, which supports generalizability and potential wide application of the definition in clinical studies. Similar to the methodology used in the original provisional definitions, our validation study assured independent data collection and case ascertainment, which is useful to avoid circular reasoning (10) . This definition is based entirely on patientreported outcomes, as favored by the Patient-Reported Outcomes Measurement Information System (PROMIS) initiative (15) . The criteria could be ascertained in person, by phone, diary entries, smartphone applications, or other devices.
Limitations of our original flare definition methodology still apply to this validation process and include the inability to properly and reliably incorporate questions about time to peak symptom intensity, which is a common component of operational flare definitions in clinical trials (8) . We previously observed that time to peak symptom intensity was a variable of poor quality that likely was influenced by the dependence on and accuracy of patient recall. Although 36% of our patients had tophi, this validated definition should be applied cautiously to such patients, who may have chronic inflammatory arthritis. We did not collect information regarding whether patients self-medicated for gout flares on the day of the assessment. We can hypothesize that patients who self-medicate are considering themselves to be in a flare state and would fulfill the patient-defined flare criterion. In addition, use of medication could affect the answers about pain, current swollen joints, or current warm joints during the evaluation. The patients used for this study were recruited from the rheumatology practices of clinicians with an interest in gout research, which may limit generalizability to other primary or secondary care settings. Finally, despite our efforts to make procedures uniform between study sites, it is likely that local practice and expertise introduced heterogeneity in how the expert rheumatologists adjudicated gout flare status. Cross-validation between sites was not possible using the resources available for this study. However, variability between sites in assessing gout is somewhat natural and speaks to the pragmatic nature of our validation approach.
In conclusion, a definition requiring fulfillment of 3 or more criteria (including patient-defined flare, pain at rest score of >3 on a 0-10 NRS, presence of at least 1 swollen joint, and presence of at least 1 warm joint) was sensitive, specific, and accurate in identifying disease flare in patients with established gout. Having a validated definition of gout flare is important to standardize outcome ascertainment in gout studies, particularly in clinical trials of urate-lowering therapies and studies of gout flare prophylaxis.
